CKD-383

DRUG5 trials

Sponsors

Chong Kun Dang Pharmaceutical

Conditions

Type 2 DiabetesType 2 Diabetes Mellitus (T2DM)Type2 Diabetes Mellitus

Phase 1

A Clinical Trial to Evaluate the Pharmacokinetic Profiles and Safety of CKD-383.

CompletedNCT04810676

Chong Kun Dang PharmaceuticalType2 Diabetes Mellitus

Start: 2021-04-16End: 2021-05-26Updated: 2021-06-10

Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D744, and D150

CompletedNCT05816759

Chong Kun Dang PharmaceuticalType 2 Diabetes

Start: 2023-05-26End: 2023-06-22Updated: 2024-01-23

Evaluate the Pharmacokinetics and Safety Between the Treatment of CKD-383 and Treatment of CKD-501, D745, D150, and D029

CompletedNCT05897216

Chong Kun Dang PharmaceuticalType 2 Diabetes

Start: 2023-07-14End: 2023-08-08Updated: 2024-01-23

Clinical Study to Evaluate the Food Effect of CKD-383 0.5/10/1000mg in Healthy Volunteers

CompletedNCT06695572

Chong Kun Dang PharmaceuticalType 2 Diabetes Mellitus (T2DM)

Start: 2024-11-06End: 2024-12-13Updated: 2025-05-21

Clinical Study to Evaluate the Food Effect of CKD-383 0.5/25/1000mg in Healthy Volunteers

CompletedNCT06695598

Chong Kun Dang PharmaceuticalType 2 Diabetes Mellitus (T2DM)

Start: 2024-11-06End: 2024-12-19Updated: 2025-05-21